M-TEER reduces heart failure hospitalization risk across all health status levels in mitral regurgitation
This study is a subgroup analysis of a randomized controlled trial evaluating mitral transcatheter edge-to-edge repair (M-TEER) using the MitraClip device versus medical therapy alone in patients with symptomatic heart failure and moderate-to-severe ventricular secondary mitral regurgitation. The analysis stratified patients by baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores into tertiles to assess whether health status influenced treatment effect.
The authors found that M-TEER reduced the risk of cardiovascular death or heart failure hospitalization across all KCCQ-CSS tertiles, with hazard ratios favoring the intervention. However, the trend across tertiles was not statistically significant. Similarly, total heart failure hospitalizations were reduced consistently. At 6 months, patients in the M-TEER group were more likely to achieve clinically meaningful improvements in KCCQ-CSS (≥5, ≥10, and ≥15 points) and less likely to experience deterioration.
Key limitations include that this is a subgroup analysis from a single RCT, and confidence intervals for some outcomes were wide, crossing 1.0. The primary outcome of the overall trial was not explicitly stated, and the P-trend for the composite endpoint was not significant, suggesting the effect may not vary by baseline health status.
Clinically, these results suggest that M-TEER may provide consistent symptomatic benefit across a range of baseline health status in appropriately selected patients. However, the uncertainty in some estimates warrants cautious application, and patient selection should remain individualized.